Przejdź do zawartości
Merck

F6636

SAFC

Nutrient Mixture F-12 Ham

Coon′s Modification, with ʟ-glutamine and zinc sulfate, without sodium bicarbonate, powder, suitable for cell culture

Synonim(y):

Ham’s F-12

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Numer MDL:
Kod UNSPSC:
12352207
NACRES:
NA.75

product name

Nutrient Mixture F-12 Ham, powder, with L-glutamine and 0.863 mg/L zinc sulfate, without sodium bicarbonate, Coon′s Modification, suitable for cell culture

Postać

powder

metody

cell culture | hybridoma: suitable
cell culture | mammalian: suitable

komponenty

phenol red: 0.00125 g/L
L-glutamine: 0.292 g/L
sodium pyruvate: 0.22 g/L
glucose: 1.802 g/L

Warunki transportu

ambient

temp. przechowywania

2-8°C

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Zastosowanie

Coon's modification of Ham's F-12 was developed for culturing hybrid cells that were produced by viral fusion. The modification consists of doubling the amino acids and pyruvate and including ascorbic acid. The salt concentrations have also been altered. The formula contains 0.863 mg/L zinc sulfate, which may render it unsuitable for culturing mouse L-cells.

Ilość

Formulated to contain 11.5 grams of powder per liter of medium.

Rekonstytucja

Supplement with 2.68 g/L sodium bicarbonate.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Środki ochrony indywidualnej

Eyeshields, Gloves, type N95 (US)


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Xiaojiao Xue et al.
Human molecular genetics, 26(16), 3116-3129 (2017-06-03)
In-frame premature termination codons (PTCs) account for ∼11% of all disease-associated mutations. PTC suppression therapy utilizes small molecules that suppress translation termination at a PTC to restore synthesis of a full-length protein. PTC suppression is mediated by the base pairing
Feng Liang et al.
SLAS technology, 22(3), 315-324 (2017-04-06)
Cystic fibrosis (CF) is a hereditary disease caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR). A large number of nearly 2000 reported mutations, including the premature termination codon (PTC) mutations, urgently require new
Kenneth A Giuliano et al.
SLAS discovery : advancing life sciences R & D, 23(2), 111-121 (2017-09-13)
Cystic fibrosis (CF) is a lethal genetic disorder caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Despite recent groundbreaking approval of genotype-specific small-molecule drugs, a significant portion of CF patients still lack effective therapeutic options that
Wren E Michaels et al.
Nucleic acids research, 48(13), 7454-7467 (2020-06-11)
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, encoding an anion channel that conducts chloride and bicarbonate across epithelial membranes. Mutations that disrupt pre-mRNA splicing occur in >15% of
Robert Rauscher et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(4) (2021-01-21)
Epistasis refers to the dependence of a mutation on other mutation(s) and the genetic context in general. In the context of human disorders, epistasis complicates the spectrum of disease symptoms and has been proposed as a major contributor to variations

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej